Istamet
formulated to target type 2 diabetes mellitus to support glycemic control.
Strengths: 50/1000mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Janumet
- Therapeutic class
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor; Biguanide Antidiabetic
- Pharmacological class
DPP-4 Inhibitor; Biguanide
- Minor side effects
nausea; diarrhoea; headache
- Moderate side effects
upper respiratory tract infection; nasopharyngitis
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
formulated to target type 2 diabetes mellitus to support glycemic control.
- Prescription status
POM
- Manufacturer
Merck Sharp & Dohme
- Onset Time
1–2 hours
- Duration
12–24 hours
- Storage instructions
Store below 25°C, away from sunlight and moisture.
- Drug interactions
Alcohol; Iodinated contrast media
- Age restrictions
Not indicated for use in children or adolescents.
Contraindications
hypersensitivity to sitagliptin; hypersensitivity to metformin; severe renal impairment; diabetic ketoacidosis; severe hepatic impairment
Precautions and warnings
monitor renal function regularly; risk of lactic acidosis; discontinue if symptoms of pancreatitis occur
Serious side effects
pancreatitis — requires immediate medical attention; lactic acidosis — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Mechanism of action
This medicine combines two active agents that work by increasing incretin levels to stimulate insulin release after meals and by reducing glucose production in the liver, effectively lowering blood sugar levels.
Pregnancy and breastfeeding
Pregnancy: should be avoided unless clearly necessary. Breastfeeding: not recommended as components may pass into breast milk.
Istamet
formulated to target type 2 diabetes mellitus to support glycemic control.
Editorial Notes
- Active ingredient(s): Sitagliptin, Metformin
- Listed indication(s): Type 2 Diabetes Mellitus
Available option
- 30 tablets - 50/1000 mg1480-50-1000-mg-17949